Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuRVO: Ranibizumab versus observation in central retinal vein occlusion
2009-012941-45Phase 3Terminated
- Sponsor
- Rigshospitalet Glostrup
- Start
- Sep 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ranibizumab in central retinal vein occlusion (CRVO) (2 arms), sponsored by Rigshospitalet Glostrup. Primary endpoint: Visual acuity at 12 months. Started Sep 2009; status: terminated.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2009-012941-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012941-45.